Quantcast

Latest Fuisz Pharma Stories

2014-04-22 08:33:20

MIAMI, April 22, 2014 /PRNewswire/ -- Fuisz Pharma llc today announced the filing of a patent application with the U.S. Patent and Trademark Office of a new system and method to allow a patient to easily and reliably self-administer ophthalmic preparations. Joseph Fuisz, Managing Member commented: "The use of Ophthalmic preparations is increasing and yet self-administration remains problematic and essentially unchanged. This invention is a simple and ingenious system to accurately...

2011-08-17 07:00:00

MIAMI, Aug. 17, 2011 /PRNewswire/ -- Fuisz Pharma (www.fuisz.com) today announced the publication of U.S. Patent Application US 20110182827 ("Method and Dosage Form to Confirm Compliant Use of a Bioactive Agent"). This patent pending is directed towards a dosage form that includes a substance that is visible to a normal light or to a special light source in the buccal or vaginal cavity in order for medical personnel to confirm compliant use of a medication. The substance leaves behind a...

2011-04-18 07:00:00

MIAMI, April 18, 2011 /PRNewswire/ -- Fuisz Pharma announced that it has secured an exclusive license for a vaginal treatment of dysmenorrhea. The exclusive license covers existing clinical work whereby a medicated tampon was used to deliver keterolac and it includes two issued United States patents. Joseph Fuisz, Managing Partner of Fuisz Pharma, stated, "We are pleased to announce this acquisition, having had a long standing interest in vaginal drug delivery, and in particular in the...

2011-02-07 07:00:00

MIAMI, Feb. 7, 2011 /PRNewswire/ -- Based on U.S. Patent 7,824,612 ("Body Fluid Analyzer and System including Same and Method for Programming Same"), Fuisz Pharma today announced the use of their patented Technology to create a new class of microchip containing smart tablets that communicate with personal body fluid analyzers. These tablets wirelessly inform a body fluid analyzer of acceptable analyte values for body fluids, set by the drug company so that the analyzer can provide alerts...

2010-12-06 07:00:00

MIAMI, Dec. 6, 2010 /PRNewswire-USNewswire/ -- Fuisz Pharma today released photos of what the clinician will see in a standard nasal otoscopic exam in the case of a patient abusing an opioid, like Oxycontin® and others, through snorting. A food safe dye included in the tablet creates easily visible, long lasting but temporary nasal stain. Crushing and snorting opioids is the most common method of opioid abuse. The photos are taken at 12 hours, 24 hours and 48 hours after...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related